BAY 43-9006: Phase I

Biomarker data from a dose-ranging Phase I trial in 66 patients showed BAY 43-9006 inhibited the Raf kinase pathway in 7 of 12 patients evaluated as measured by suppression of ERK phosphorylation leve...